1. Pink Sheet
  2. >>Geography
  3. >>Europe

New EU Approach On Duplicate Marketing Authorizations Prompts Questions

 
• By Vibha Sharma

The European Commission says there is no automatic link between the introduction of a duplicate marketing authorization by the holder of the original medicinal product (be it a chemical or a biological medicinal product) and the increased availability of said medicine. 

Original and Copy concept. Rubber Stamp on desk in the Office. Business and work background
The number of duplicate marketing authorization requests has been increasing • Source: Shutterstock

The European Commission has changed how it handles applications from originator companies for duplicate marketing authorizations of chemical medicinal products to ensure that these are granted only on an exceptional basis. It already follows this approach for duplicate MAs of biological medicines.

The new approach could prove tricky for companies to comply with, according to the law firm, Arnold & Porter, which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

Belgium Competition Authority Tackles Reimbursement Barriers For Combination Drugs

 
• By Francesca Bruce

The Belgian Competition Authority has set out guidance on how pharmaceutical companies can share information on combination therapies when seeking their reimbursement.

EMA Backs 14 New Drugs, Confirms Atropine Rejection For Myopia

 
• By Vibha Sharma

The European Medicines Agency’s human medicines committee has recommended 14 new drugs for marketing approval, including treatments for RSV, menopause, diabetes, and generalized myasthenia gravis.

Speed, Reach And Impact: New Metrics To Drive EU Clinical Trials Reform

 
• By Vibha Sharma

Clinical trials in the EU will be measured against new benchmarks from 2026 to identify how the bloc’s clinical research environment compares with that of other regions, and to identify areas for improvement.

EU-Level Efforts To Mitigate Drug Shortages Unsuccessful, Audit Reveals

 
• By Eliza Slawther

Actions taken by the European Commission and European Medicines Agency to tackle critical shortages of medicines have not succeeded in practice and further systemic improvements are required to address supply issues, a report from the European Court of Auditors has found.

More from Geography

Belgium Competition Authority Tackles Reimbursement Barriers For Combination Drugs

 
• By Francesca Bruce

The Belgian Competition Authority has set out guidance on how pharmaceutical companies can share information on combination therapies when seeking their reimbursement.

ACIP Weakened COVID-19 Vaccine Advice, But Less Than Rhetoric May Suggest

 
• By Sarah Karlin-Smith

The new recommendations should not change insurance coverage, but the tone of the meeting frustrated many medical experts, because of the negative comments on the vaccines.

Inexperience And Confusion: ACIP Struggles To End MMRV, Hep B Debates

 
• By Bridget Silverman

Confusion, inconsistency and strongly held views complicated the CDC's Advisory Committee on Immunization Practices' votes to change vaccine recommendations for the measles, mumps, rubella, varicella vaccine in young children and tabling of a vote on hepatitis B vaccine at birth.